Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Western Europe Firm Invests Up to €12M in Therapeutics Companies, Open to All Types of Modalities and Indication Areas

21 May

A firm based in Western Europe currently manages three funds, the newest of which closed in 2020 and focuses on investments in Europe-based therapeutics and medical innovation. The firm invests in Europe and North America, and typically allocates €5 to €12 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics. The firm is agnostic regarding technologies and indication areas, and typically invests early but is open to companies with assets ranging from preclinical development through Phase II.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Western-Europe Based Private Wealth Firm Invests in Therapeutics & Digital Therapeutics, Most Interested in Oncology

14 May

A private wealth investment vehicle based in Western Europe is looking to invest in therapeutics companies as well as companies developing digital therapeutics or therapeutic-enabling technologies. The firm is primarily interested in early stage, pre-clinical breakthrough technologies and, especially for digital-based companies, capital efficient business models. While the firm has invested primarily within Western Europe up until now, The firm is willing to consider companies in other geographies if they find the technology compelling. For a first investment, the firm invests, on average, 2M, but can invest smaller or larger amounts, depending on the company and its needs.

The firm is looking for companies in the broader therapeutics space. The firm is interested not only in more traditional therapeutics technologies, but also in digital therapeutics and digital therapeutic-enabling technologies, drug development platforms, including digital and genomics-based drug development technologies, and in cell and gene therapy manufacturing technologies. The firm has historically invested primarily in technologies relating to oncology, but will consider any indication.

The firm takes an active role with the companies in which they invest. The firm frequently leads rounds, and supports and mentors the early stage companies, often either taking a board seat themselves or finding an expert to serve on the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Asia-Based Medical Technology Developer Seeks In-Licensing & Investment Opportunities in Early-Stage Medtech

14 May

An investor and developer of medical technologies headquartered in Asia with a subsidiary located in USA looks for new in-licensing or investment opportunities in cutting-edge medical device innovations from North America, Asia, and Europe, with no set cap on investment size.
With vertical integration of experienced medical professionals, talented engineers, and international infrastructure, the firm is dedicated to developing high value and high impact medical devices.

Focusing on minimally invasive surgical devices and healthcare information technologies, the firm invests in companies at any stage of development, from ideation, early product design, prototyping, preclinical testing, clinical trials to commercialization. The firm prefers disease states with sizable patient population, including but not limited to cardiovascular or peripheral vascular disease, orthopedics, neurosurgery, obesity, gastroenterology, hematology, nephrology, gynecology, urology, and plastic surgery.

The firm is looking for collaborations with competent entrepreneurs, physicians, companies and investors and willing to lead and co-invest in med-tech companies to develop novel solutions.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: USA PE Firm Seeks Growth Stage Opportunities in Devices, Diagnostics, Digital Health for Investment, Acquisitions, In-Licensing

14 May

A private equity firm founded in the USA invests in companies with high growth potential. The firm also considers in-licensing of technologies and strategic acquisitions. For equity investments, the firm prefers that companies are located in the Eastern US and Midwest, but for acquisitions and in-licensing, the firm will consider companies located around the globe. The firm also has an early-stage focused fund through which the firm makes angel investments into high potential, early-stage companies. With this fund, the firm typically invests up to $250K in preferred equity.

The firm primarily focuses on the following sectors: Diagnostics (including digital), Pharma Services/Outsourcing, Digital Health, and Medical Devices. The firm has a strong preference for companies working with platform technologies. For equity investments, the firm looks for companies that have reached commercialization. With regards to their early-stage fund, the firm primarily seeks companies in healthcare services and SaaS outsourcing businesses.

The firm is looking for experienced management teams with domain expertise and leadership skills that are capable of taking the company to the next value inflection point or additional capital raise. The firm is interested in company that are profitable or near breakeven and have demonstrated substantial opportunity for growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: China-Based Holding Company Invests in Pre-Series A to Pre-IPO Therapeutics, Medical Devices, Diagnostics Companies With China Angle

14 May

An investment holding company based in China specializes in equity investment, debt financing, and equity investment services. With capital commitment from both public and private investors, the firm currently has total assets under management of over RMB 29 billion (USD $4.5 billion). Typical equity allocations range from US$2-6 million in an early-stage company, while the firm can participate from pre-series A to pre-IPO financing rounds. The firm is currently seeking opportunities from China, the US, and the EU.

The firm currently focuses on pharmaceuticals, medical devices, and IVD tools in late clinical development or early preclinical stage with high entry battier and market potential.

The firm is looking for experienced management teams. The firm typically syndicates with other investors and takes 10%-20% minority stake in a financing round. Board representation is often required. The firm prefers China-based companies, Chinese-owned foreign businesses, or products with a China-angle; however, this is not a requirement. The firm can provide its expertise to help with registration, distribution, M&A, and formation of the joint venture and strategic partnerships in the country.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: China Venture Fund Invests Up to $25M in Therapeutics, Devices, Diagnostics, with Strong Interests in Oncology, Metabolic Disease, etc.

7 May

A sector-exclusive life sciences venture and growth equity fund focused on Asia, particularly China, is currently investing from its latest fund closed in 2019. The firm is stage agnostic, investing as early as seed, growth, and up to pre-IPO opportunities. The firm has a team of investment professionals all with healthcare background. Investment size is USD $5-25 million per company. The firm prefers to lead or co-lead a financing round, and while the firm focuses on China they also consider opportunities from USA.

In life sciences, the firm is focused on therapeutics with an emphasis on oncology, metabolic disorders, cell therapy, and biologics, etc. The firm is also interested in medical devices and diagnostics. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA.

The firm is seeking experienced management teams that are going rapidly and emerging as market leaders.  The firm is seeking companies developing technologies that are truly based on high quality science, but also aligned with the potential of attractive financial return. Because the firm focuses its activities in China, the firm will prefer companies outside of China to have a strong China angle. The firm typically requires a board seat or observation rights post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 2: USA-Based Private Investment Firm Looking for Medical Devices, Diagnostics, and Digital Health Startups Across North America

7 May

A USA-based private investment firm is focused on healthcare companies. The firm makes seed, venture, and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $100K to $1M per portfolio company. The firm generally acts as the lead investor and is open to investing in syndicates. The firm is open to opportunities across North America and is actively seeking new investment opportunities.

The firm is currently seeking to invest in medical devices, diagnostics, digital health, and software. The firm is also interested in reformulated and repurposed drugs that have mitigated risk. For medical devices, the firm is opportunistic in terms of subsectors. Ideally, the product has a prototype and 510(k) regulatory pathway. The firm is open to investing in any indication, including orphan diseases; the dental field is of interest.

The firm seeks a strong and experienced management team. The firm may take a board seat where appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: